ABCL-579 Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study

Authors: Paskiewicz-Kozik, Ewa, Glimelius, Ingrid, Moreira, Claudia, Garrido, Marcelo, Ernst, Daniel, Jurczak, Wojciech, Merryman, Reid, Seog Kim, Won, Ozcan, Muhit, Santoro, Armando, Sawalha, Yazeed, Berkovits, Alejandro, Ren, Yixin, Ogbu, Uzor, Yusuf, Rushdia, Luigi Zinzani, Pier

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S483-S484

Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study

Authors: Paskiewicz-Kozik, Ewa, Glimelius, Ingrid, Moreira, Claudia, Garrido, Marcelo, Ernst, Daniel, Jurczak, Wojciech, Merryman, Reid, Seog Kim, Won, Ozcan, Muhit, Santoro, Armando, Sawalha, Yazeed, Berkovits, Alejandro, Ren, Yixin, Ogbu, Uzor, Yusuf, Rushdia, Luigi Zinzani, Pier

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S218-S218

Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma

Authors: Berkovits, Alejandro ^*, Yanez, Eduardo ^*, Rojas, Christine ^*, Gazitua, Raimundo ^*, Cazap, Nicolás ^*, Sureda, Anna, Saleem, Rao ^*, Meng, Robin ^*, Xu, Jing ^*, Streit, Michael ^*, Barboux, Valentine ^*, Ahmed, Sairah

Source: In Blood 15 November 2022 140 Supplement 1:12020-12021

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.

Authors: Zinzani, Pier Luigi¹ (AUTHOR), Mayer, Jiri² (AUTHOR), Benjamini, Ohad³ (AUTHOR), Berkovits, Alejandro⁴ (AUTHOR), Glimelius, Ingrid⁵ (AUTHOR), Stevens, Don A.⁶ (AUTHOR), Chaudhry, Arvind⁷ (AUTHOR), Muzaffer Demir, Ahmet⁸ (AUTHOR), Garcia Sanz, Ramón⁹ (AUTHOR), Seog Kim, Won¹⁰ (AUTHOR), Li, Fei¹¹ (AUTHOR), Halka, Janusz¹² (AUTHOR), Marin-Niebla, Ana¹³ (AUTHOR), Ozcan, Muhit¹⁴ (AUTHOR), Paszkiewicz-Kozik, Ewa¹⁵ (AUTHOR), Santoro, Armando¹⁶ (AUTHOR), Ren, Yixin¹⁷ (AUTHOR), Ogbu, Uzor¹⁷ (AUTHOR), Marinello, Patricia¹⁷ (AUTHOR), Jurczak, Wojciech¹⁸ (AUTHOR)

Source: Journal of Clinical Oncology. 2023 Supplement 16, Vol. 41, pTPS7595-TPS7595. 1p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience.

Authors: Cordova-Delgado, Miguel, Pinto, Mauricio P., Regonesi, Carlos, Cereceda, Luis, Reyes, José Miguel, Itriago, Laura, Majlis, Alejandro, Rodríguez, Pablo, Fassler, André, Mahave, Mauricio, León, María Elisa, Gallardo, Jorge, Rodríguez Z., María Paz, Berkovits, Alejandro, Manque, Patricio, Ríos, Juvenal A., Garcia-Bloj, Benjamín, Garrido, Marcelo

Source: Journal of Personalized Medicine; Feb2022, Vol. 12 Issue 2, pN.PAG-N.PAG, 1p

Subject Terms: CANCER patients, PROGRESSION-free survival, TUMOR classification, BIOMARKERS, IMMUNE checkpoint inhibitors, INDIVIDUALIZED medicine, DEVELOPED countries

Geographic Terms: CHILE

This result is not displayed to guests.
Login for full access.